{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"1.0","value":"0.75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Kaplan-Meier method, percent of patients alive and progression-free at 2-years","dispersionType":"90% Confidence Interval","groups":[{"description":"* A treatment cycle is defined as 28 consecutive days.\n* Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months.\n\nNivolumab: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and\n\nLenalidomide: Oral, predetermined dosage, Days 1-21 of cycle 1-12\n\nDexamethasone: Oral, Days 1, 8, 15 of cycle 1-6","id":"OG000","title":"Nivolumab, Lenalidomide, Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline to disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died, up to 24 months post initiation of therapy.","title":"Progression Free Survival (PFS) Probability at 2-years","type":"SECONDARY","unitOfMeasure":"probability"}